Model-averaged coefficients, significance, and relative importance (RI) of the predictor variables for the GLMMs to evaluate effects on: (A) overall pollinator abundance; (B) fruit... by Carmelo Gómez-Martínez (9384385)

Average Gait Speed (A), Cadence (B), Step Length (C), and Walk Ratio (D) across Terrains; Violin plots with individual participant data of A) gait speed, B) cadence, C) average ste... by Benjamin S. Killen (22766029)

S1 Data - by Miki Doi (15347878)

Subjects:

S1 Fig - by Miki Doi (15347878)

Subjects:

Semiannual analysis of monthly use of sterile blood transfer devices. by Miki Doi (15347878)

Subjects:

Semiannual analysis of monthly use of skin disinfection swab sets in the hospital. by Miki Doi (15347878)

Subjects:

Changes in the monthly contamination rate (per set) in blood culture (BC). by Miki Doi (15347878)

Subjects:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

A representative ultrasound axis image. by Eun-Seon Yang (19751340)

Subjects:

BMI groups by SES. by Krystal Hunter (6820052)

Subjects:

BMISES_Data_Part2. by Krystal Hunter (6820052)

Subjects:

Logistic regression for LSES population. by Krystal Hunter (6820052)

Subjects:

Logistic regression for HSES population. by Krystal Hunter (6820052)

Subjects:

Logistic regression for overall population. by Krystal Hunter (6820052)

Subjects:

BMISES_Data_Part1. by Krystal Hunter (6820052)

Subjects:

Baseline characteristics of HSES/LSES population. by Krystal Hunter (6820052)

Subjects:

Baseline characteristics of overall population. by Krystal Hunter (6820052)

Subjects:

Diagram of study population. by Krystal Hunter (6820052)

Subjects: